Big Pharma hits pause on trials in Russia, Ukraine as they ramp up humanitarian aid
Pharma companies across the board are rallying to provide humanitarian aid amid a bloody war in Ukraine that’s taken the lives of at least hundreds of civilians.
Yet as clinical trials remain under threat of disruption and a corporate exodus out of Russia continues, all the signs point to significant challenges ahead for Big Pharma.
Ruud Dobber, head of AstraZeneca’s biopharmaceuticals business unit, revealed earlier this week at Cowen’s Healthcare Conference that the pharma giant has suspended enrollment of some clinical trials in Ukraine and Russia as the war enters its 13th day.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.